Aleeto in Acute ISchemic Stroke：A RandomISed Controlled Clinical Trial

Summary

This study is a prospective, double-blind, 1:1:1 randomized controlled study aimed at evaluating the efficacy and safety of Aleeto treatment compared to placebo in improving the NIHSS score at 14 days in patients with moderate to severe acute ischemic stroke. It also aims to explore the neuroprotective effects of Aleeto in moderate to severe acute ischemic stroke and provide data support and evidence for future clinical trials and evidence-based medicine.

Timeline

Start

2025-03-21

Primary completion

2025-11-30

Completion

2026-01-31

Drugs

Indications